Cargando…

The Revival of Aztreonam in Combination with Avibactam against Metallo-β-Lactamase-Producing Gram-Negatives: A Systematic Review of In Vitro Studies and Clinical Cases

Infections caused by metallo-β-lactamase (MBL)-producing Enterobacterales and Pseudomonas are increasingly reported worldwide and are usually associated with high mortality rates (>30%). Neither standard therapy nor consensus for the management of these infections exist. Aztreonam, an old β-lacta...

Descripción completa

Detalles Bibliográficos
Autores principales: Mauri, Carola, Maraolo, Alberto Enrico, Di Bella, Stefano, Luzzaro, Francesco, Principe, Luigi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8388901/
https://www.ncbi.nlm.nih.gov/pubmed/34439062
http://dx.doi.org/10.3390/antibiotics10081012
_version_ 1783742737824088064
author Mauri, Carola
Maraolo, Alberto Enrico
Di Bella, Stefano
Luzzaro, Francesco
Principe, Luigi
author_facet Mauri, Carola
Maraolo, Alberto Enrico
Di Bella, Stefano
Luzzaro, Francesco
Principe, Luigi
author_sort Mauri, Carola
collection PubMed
description Infections caused by metallo-β-lactamase (MBL)-producing Enterobacterales and Pseudomonas are increasingly reported worldwide and are usually associated with high mortality rates (>30%). Neither standard therapy nor consensus for the management of these infections exist. Aztreonam, an old β-lactam antibiotic, is not hydrolyzed by MBLs. However, since many MBL-producing strains co-produce enzymes that could hydrolyze aztreonam (e.g., AmpC, ESBL), a robust β-lactamase inhibitor such as avibactam could be given as a partner drug. We performed a systematic review including 35 in vitro and 18 in vivo studies on the combination aztreonam + avibactam for infections sustained by MBL-producing Gram-negatives. In vitro data on 2209 Gram-negatives were available, showing the high antimicrobial activity of aztreonam (MIC ≤ 4 mg/L when combined with avibactam) in 80% of MBL-producing Enterobacterales, 85% of Stenotrophomonas and 6% of MBL-producing Pseudomonas. Clinical data were available for 94 patients: 83% of them had bloodstream infections. Clinical resolution within 30 days was reported in 80% of infected patients. Analyzing only patients with bloodstream infections (64 patients), death occurred in 19% of patients treated with aztreonam + ceftazidime/avibactam. The combination aztreonam + avibactam appears to be a promising option against MBL-producing bacteria (especially Enterobacterales, much less for Pseudomonas) while waiting for new antimicrobials.
format Online
Article
Text
id pubmed-8388901
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-83889012021-08-27 The Revival of Aztreonam in Combination with Avibactam against Metallo-β-Lactamase-Producing Gram-Negatives: A Systematic Review of In Vitro Studies and Clinical Cases Mauri, Carola Maraolo, Alberto Enrico Di Bella, Stefano Luzzaro, Francesco Principe, Luigi Antibiotics (Basel) Review Infections caused by metallo-β-lactamase (MBL)-producing Enterobacterales and Pseudomonas are increasingly reported worldwide and are usually associated with high mortality rates (>30%). Neither standard therapy nor consensus for the management of these infections exist. Aztreonam, an old β-lactam antibiotic, is not hydrolyzed by MBLs. However, since many MBL-producing strains co-produce enzymes that could hydrolyze aztreonam (e.g., AmpC, ESBL), a robust β-lactamase inhibitor such as avibactam could be given as a partner drug. We performed a systematic review including 35 in vitro and 18 in vivo studies on the combination aztreonam + avibactam for infections sustained by MBL-producing Gram-negatives. In vitro data on 2209 Gram-negatives were available, showing the high antimicrobial activity of aztreonam (MIC ≤ 4 mg/L when combined with avibactam) in 80% of MBL-producing Enterobacterales, 85% of Stenotrophomonas and 6% of MBL-producing Pseudomonas. Clinical data were available for 94 patients: 83% of them had bloodstream infections. Clinical resolution within 30 days was reported in 80% of infected patients. Analyzing only patients with bloodstream infections (64 patients), death occurred in 19% of patients treated with aztreonam + ceftazidime/avibactam. The combination aztreonam + avibactam appears to be a promising option against MBL-producing bacteria (especially Enterobacterales, much less for Pseudomonas) while waiting for new antimicrobials. MDPI 2021-08-20 /pmc/articles/PMC8388901/ /pubmed/34439062 http://dx.doi.org/10.3390/antibiotics10081012 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Mauri, Carola
Maraolo, Alberto Enrico
Di Bella, Stefano
Luzzaro, Francesco
Principe, Luigi
The Revival of Aztreonam in Combination with Avibactam against Metallo-β-Lactamase-Producing Gram-Negatives: A Systematic Review of In Vitro Studies and Clinical Cases
title The Revival of Aztreonam in Combination with Avibactam against Metallo-β-Lactamase-Producing Gram-Negatives: A Systematic Review of In Vitro Studies and Clinical Cases
title_full The Revival of Aztreonam in Combination with Avibactam against Metallo-β-Lactamase-Producing Gram-Negatives: A Systematic Review of In Vitro Studies and Clinical Cases
title_fullStr The Revival of Aztreonam in Combination with Avibactam against Metallo-β-Lactamase-Producing Gram-Negatives: A Systematic Review of In Vitro Studies and Clinical Cases
title_full_unstemmed The Revival of Aztreonam in Combination with Avibactam against Metallo-β-Lactamase-Producing Gram-Negatives: A Systematic Review of In Vitro Studies and Clinical Cases
title_short The Revival of Aztreonam in Combination with Avibactam against Metallo-β-Lactamase-Producing Gram-Negatives: A Systematic Review of In Vitro Studies and Clinical Cases
title_sort revival of aztreonam in combination with avibactam against metallo-β-lactamase-producing gram-negatives: a systematic review of in vitro studies and clinical cases
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8388901/
https://www.ncbi.nlm.nih.gov/pubmed/34439062
http://dx.doi.org/10.3390/antibiotics10081012
work_keys_str_mv AT mauricarola therevivalofaztreonamincombinationwithavibactamagainstmetalloblactamaseproducinggramnegativesasystematicreviewofinvitrostudiesandclinicalcases
AT maraoloalbertoenrico therevivalofaztreonamincombinationwithavibactamagainstmetalloblactamaseproducinggramnegativesasystematicreviewofinvitrostudiesandclinicalcases
AT dibellastefano therevivalofaztreonamincombinationwithavibactamagainstmetalloblactamaseproducinggramnegativesasystematicreviewofinvitrostudiesandclinicalcases
AT luzzarofrancesco therevivalofaztreonamincombinationwithavibactamagainstmetalloblactamaseproducinggramnegativesasystematicreviewofinvitrostudiesandclinicalcases
AT principeluigi therevivalofaztreonamincombinationwithavibactamagainstmetalloblactamaseproducinggramnegativesasystematicreviewofinvitrostudiesandclinicalcases
AT mauricarola revivalofaztreonamincombinationwithavibactamagainstmetalloblactamaseproducinggramnegativesasystematicreviewofinvitrostudiesandclinicalcases
AT maraoloalbertoenrico revivalofaztreonamincombinationwithavibactamagainstmetalloblactamaseproducinggramnegativesasystematicreviewofinvitrostudiesandclinicalcases
AT dibellastefano revivalofaztreonamincombinationwithavibactamagainstmetalloblactamaseproducinggramnegativesasystematicreviewofinvitrostudiesandclinicalcases
AT luzzarofrancesco revivalofaztreonamincombinationwithavibactamagainstmetalloblactamaseproducinggramnegativesasystematicreviewofinvitrostudiesandclinicalcases
AT principeluigi revivalofaztreonamincombinationwithavibactamagainstmetalloblactamaseproducinggramnegativesasystematicreviewofinvitrostudiesandclinicalcases